YONKERS, NY--(Marketwire - Jan 4, 2013) - ContraFect Corporation, developing biotherapeutics for life-threatening infectious diseases, today announced that Robert Nowinski, the Company's founder and chief executive officer, and Julia P. Gregory, the Company's executive vice president and chief financial officer, will present a corporate overview at the 5th Annual Biotech Showcase taking place at the Parc 55 Wyndham Hotel in San Francisco, CA from January 7-9, 2013. Dr. Nowinski and Ms. Gregory will discuss ContraFect's novel approach to drug resistant Staph infections and clinical plans for its lead product, CF-301. The Company's presentation will take place on Tuesday, January 8th at 9:45 am PST.
About Biotech Showcase:
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.
ContraFect Corporation is a biotechnology company pioneering the use of Lysins and Monoclonal Antibodies to treat life-threatening infectious diseases. ContraFect's initial products include agents to treat diseases such as MRSA (drug-resistant staphylococcus bacteria) and influenza. Its scientific strategy focuses on the use of combination therapies, where it believes that the company's products will overcome high rates of mutation and resistance observed in microbes.
Safe Harbor Statement
This release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward looking statements. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.